Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 1Advanced Solid Tumor Malignancies 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × navicixizumab × Clear all
NCT05043402 2022-08-15

A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

OncXerna Theraputics, Inc.

Phase 3 Unknown
400 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03030287 2020-09-03

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Mereo BioPharma

Phase 1 Completed
44 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02298387 2020-08-11

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Mereo BioPharma

Phase 1 Completed
71 enrolled
Other solid neoplasm

Advanced Solid Tumor Malignancies

NCT03035253 2020-08-11

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Mereo BioPharma

Phase 1 Terminated
16 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡